Beijing Primegene Therapeutics Co. Ltd. has discovered NLRP3 inflammasome inhibitors reported to be useful for the treatment of sepsis, stroke, atherosclerosis, gout, Alzheimer's disease, Parkinson’s disease, type I diabetes and cancer, among others.